Legend Biotech (ä¼ å„ēē©) Follow-On Offering - Untimely Raise
Legend Biotech Corp (LEGN US) a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is looking US$300m in its follow-on...
457 Views
Global #1 Gene Synthesis Provider, But The Stock Is Fairly Valued
Valuation of Genscript Biotech (1548 HK) reached ~$9 billion in Hong Kong. We do believe the stock has ~11% limited upside potential with free cash...
450 Views
Yidu Tech IPO Valuation: Attractive at the Low-End but Superior Growth Profile Justifies the Premium
The big data and AI solutions provider for healthcare sector in China, Yidu Tech has set the terms for its IPO and in this insight, we examine Yidu...
787 Views
Legend Biotech IPO: Pass on Valuation
Legend Biotech (LEGN US)Ā is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...
624 Views
ECM Weekly (24 May 2020) - NetEase and JD Homecoming, Legend Biotech, Nongfu Spring, Yeahka
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. The talk...
433 Views